Articles tagged "Co-stimulation"

2016 American Transplant Congress
Absence of Host CD137 Signaling Converts Chronic GVHD Toward Acute GVHD.
H. Cho,^1,3 J. Lee,^1,4 J. Kim,¹ U. Moon,¹ B. Kwon,^1,2 S. Park,³ K. Park.⁴
¹Biomedical Research Center, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan, Republic of Korea; ²School of Biological Sciences, University of Ulsan, Ulsan, Republic of Korea; ³Department of Surgery, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan, Republic of Korea; ⁴Department of Internal Medicine, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan, Republic of Korea.
CD137 functions mainly as a costimulatory molecule for T cell activation. However, its functions have been found in a variety of other immune and nonimmune…
2016 American Transplant Congress
Long-Lasting Skin Allograft Tolerance Induced and Maintained by Short-Term Vascularized Bone Marrow Transplant in a Mouse Model.
C.-H. Lin,¹ M. Anggelia,¹ H.-Y. Cheng,¹ Y.-L. Wang,¹ W.-Y. Chuang,¹ C.-H. Lin,¹ G. Brandacher.²
¹Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan; ²Department of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD.
Background: Accumulating evidences indicate that vascularized bone marrow transplantation (VBMT) plays a critical role in inducing tolerance of vascularized composite allografts (VCA). Recipients with long-term…
2016 American Transplant Congress
A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.
A. Guasch,¹ H. Xu,² A. Mehta,¹ A. Ghali,¹ S. Mead,¹ H. Gebel,¹ R. Bray,¹ C. Larsen,¹ T. Pearson,¹ A. Kirk.²
¹Emory Transplant Center, Atlanta, GA; ²Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…
2016 American Transplant Congress
Tofacitinib Delivered by Solid Lipid Nanoparticles Inhibits Dendritic Cell Maturation and Their Allostimulatory Capacity.
J. Budihardjo,¹ M. Iglesias,¹ J. Walch,¹ X. Calderon-Colon,² W. Lee,¹ G. Brandacher,¹ J. Patrone,² G. Raimondi.¹
¹Plastic Surgery, Johns Hopkins Medical Institutions, Baltimore, MD; ²Applied Physics Laboratory, Johns Hopkins University, Laurel, MD.
BackgroundComplications caused by long-term immunosuppression remain a major concern for transplant patients. To optimize controlled and accurate dosing, we investigated an innovative drug delivery method…
2016 American Transplant Congress
Selective Deletion of Notch2 on B Cells Abrogates Alloantibody Production in Fully MHC-Mismatched Cardiac and Skin Transplant Models.
N. Murakami, C. Magee, T. Borges, J. Azzi, L. Riella.
Schuster Transplantation Research Center, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
Alloantibody-mediated injury remains a major challenge for the improvement of long-term graft survival and there is no effective therapy to prevent alloantibody generation post-transplant. The…
2016 American Transplant Congress
CD57+ CD4 T Cells Persist in the Periphery Following Kidney Transplantation.
J. Espinosa,^1,2 L. Stempora,¹ R. Townsend,³ A. Kirk.¹
¹Duke University, Durham; ²Emory University, Atlanta; ³Bristol-Meyers Squibb, Princeton.
Purpose: We have shown that CD57+PD1- CD4 T cells play a role in belatacept-resistant rejection, but their mechanism of action is incompletely defined. Potential mechanisms…
2016 American Transplant Congress
Clinical and Immunologic Assessments of Immune Responses in a Liver Transplant Patient with CD40L Deficiency and Hyper IgM Syndrome.
M. Tseng,¹ S. Ge,¹ R. Roberts,² C. Kuo,² J. Choi,¹ N. Nissen,¹ M. Chu,¹ I. Kim,¹ B. Shin,¹ M. Toyoda,¹ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pediatrics & Immunology, UCLA, Los Angeles, CA.
Introduction: Monoclonal antibodies that disrupt CD40/CD40 ligand (CD40L) interactions are likely to have utility in human transplantation. However, the extent of the immunosuppressive effects of…
2016 American Transplant Congress
CTLA4 Negatively Regulates Donor-Reactive CXCR5+PD1+ T Follicular Helper Cell Responses Following Transplantation.
I. Badell,¹ D. Liu,¹ S. Suchard,² S. Nadler,² M. Ford.¹
¹Emory Transplant Center, Atlanta; ²Bristol-Myers Squibb, Princeton.
Costimulation blockade of the CD28 pathway in the form of CTLA4Ig is known to attenuate T cell dependent antibody responses. T follicular helper (Tfh) cells…
2016 American Transplant Congress
The Property of Modulatory T Cells Generated by Mixed Lymphocyte Culture with CD154 Blockade.
K. Hotta, T. Oura, B. Cosimi, T. Kawai.
Center for Transplantation Science, Massachusetts General Hospital, Boston, MA.
Background:Regulatory T cell (Treg) immunotherapy has been applied to minimize the immunosuppressive drugs in clinical transplantation. To avoid contamination of CD4+CD25- T cells, only highly…
2016 American Transplant Congress
Post-Trial Experience with Belatacept: A Large Single Center Experience.
A. Adams, C. Garrett, J. Goldstein, R. Zhang, A. Guasch, S. Pastan, R. Patzer, A. Kirk, T. Pearson, C. Larsen.
Emory Transplant Center, Atlanta, GA.
Evaluation of belatacept in clinical trials revealed significant improvements in renal function and cardiovascular risk leading to superior survival. Despite these proven benefits higher rates…